Hallmarks of cancer: new dimensions

D Hanahan - Cancer discovery, 2022 - aacrjournals.org
The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity
of cancer phenotypes and genotypes into a provisional set of underlying principles. As …

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

KJ Falkenberg, RW Johnstone - Nature reviews Drug discovery, 2014 - nature.com
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are
often caused by genetic defects that result in functional deregulation of epigenetic proteins …

[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - cell.com
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

Differentiation therapy revisited

H De Thé - Nature Reviews Cancer, 2018 - nature.com
The concept of differentiation therapy emerged from the fact that hormones or cytokines may
promote differentiation ex vivo, thereby irreversibly changing the phenotype of cancer cells …

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

MM Coudé, T Braun, J Berrou, M Dupont… - …, 2015 - pmc.ncbi.nlm.nih.gov
The bromodomain (BRD) and extraterminal (BET) proteins including BRD2, BRD3 and
BRD4 have been identified as key targets for leukemia maintenance. A novel oral inhibitor of …

[HTML][HTML] Roles of histone deacetylases and inhibitors in anticancer therapy

FA Verza, U Das, AL Fachin, JR Dimmock, M Marins - Cancers, 2020 - mdpi.com
Histones are the main structural proteins of eukaryotic chromatin. Histone acetylation/
deacetylation are the epigenetic mechanisms of the regulation of gene expression and are …

HOXA5 counteracts stem cell traits by inhibiting Wnt signaling in colorectal cancer

P Ordóñez-Morán, C Dafflon, M Imajo, E Nishida… - Cancer cell, 2015 - cell.com
Hierarchical organization of tissues relies on stem cells, which either self-renew or produce
committed progenitors predestined for lineage differentiation. Here we identify HOXA5 as an …

An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1

S Al-Harbi, M Aljurf, M Mohty, F Almohareb… - Blood …, 2020 - ashpublications.org
Acute myeloid leukemia (AML) with t (8; 21)(q22; q22. 1); RUNX1-RUNX1T1, one of the core-
binding factor leukemias, is one of the most common subtypes of AML with recurrent genetic …

Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies

HA Hou, HF Tien - Journal of biomedical science, 2020 - Springer
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

Differentiation therapy of myeloid leukemia: four decades of development

V Madan, HP Koeffler - Haematologica, 2020 - pmc.ncbi.nlm.nih.gov
Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …